欢迎您!
东篱公司
退出
申报数据库
申报指南
立项数据库
成果数据库
期刊论文
会议论文
著 作
专 利
项目获奖数据库
位置:
成果数据库
>
期刊
> 期刊详情页
Bruton Tyrosine Kinase Is a Therapeutic Target in Stem-like Cells from Multiple Myeloma.
ISSN号:0008-5472
期刊名称:Cancer Research
时间:2015.1.14
页码:594-604
相关项目:维甲酸受体α作为靶向治疗骨髓瘤干细胞的新靶点的研究
作者:
Xu, Hongwei|Huang, Junwei|Tao, Yi|Hao, Mu|Franqui, Reinaldo|Levasseur, Dana|Janz, Siegfried|Tricot, Guido|Zhan, Fenghuang|
同期刊论文项目
维甲酸受体α作为靶向治疗骨髓瘤干细胞的新靶点的研究
期刊论文 17
同项目期刊论文
[Myeloma cancer stem cells:the new target for multiple myeloma].
Early versus deferred treatment for smoldering multiple myeloma: a meta-analysis of randomized
多发性骨髓瘤的诊断进展与分期
Lenalidomide after stem-cell transplantation for multiple myeloma: a meta-analysis of randomize
Myeloma cells resistance to NK cell lysis mainly involves an HLA class I-dependent mechanism.
Synergistic activity of carfilzomib and panobinostat in multiple myeloma cells via modulation of ROS
Smoldering multiple myeloma
Proteasome inhibitor carfilzomib interacts synergistically with histone deacetylase inhibitor v
ALDH1 activity identifies tumor-initiating cells and links to chromosomal instability signature
RARalpha2 expression confers myeloma stem cell features.
Down-regulation of 11beta-hydroxysteroid dehydrogenase type 2 by bortezomib sensitizes Jurkat leukem
蛋白酶体抑制剂治疗多发性骨髓瘤现状
Proteasome inhibitor carfilzomib interacts synergistically with histone deacetylase inhibitor vorinostat in Jurkat T-leukemia cells
Myeloma cells resistance to NK cell lysis mainly involves an HLA class I-dependent mechanism